Neuroblastoma: trials for referral
132 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
132 trials shown
No phase1 site
RecruitingUnited States
NCT01005654
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
National Cancer Institute (NCI)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT06176989
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
National Cancer Institute (NCI)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 13 sites
RecruitingUnited States
NCT04837547
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
University of Florida
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 1/23 sites
RecruitingUnited States
NCT07437963
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
National Cancer Institute (NCI)
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingGermany
NCT07897968
GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
Universität Münster
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 2/320 sites
RecruitingCanada, Germany, Denmark, Spain, France, United Kingdom
NCT07549321
A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
Renaissance Pharma Ltd.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06041516
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
National Cancer Institute (NCI)
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govEarly Phase 113 sites
RecruitingCanada
NCT06942039
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
C17 Council
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 1/272 sites
RecruitingAustralia, Belgium, Brazil, Canada, Chile, Colombia
NCT06395103
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Merck Sharp & Dohme LLC
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 3180 sites
RecruitingAustralia, Canada, New Zealand, Puerto Rico, United States
NCT06172296
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “No prior anti-cancer therapy except as outlined below:”
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 1/21 site
Not yet recruitingChina
NCT04637503
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
Shenzhen Geno-Immune Medical Institute
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT02605421
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
Masonic Cancer Center, University of Minnesota
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT02508038
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT03382158
International PPB/DICER1 Registry
Children's Hospitals and Clinics of Minnesota
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06995872
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
National Cancer Institute (NCI)
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govNo phase35 sites
RecruitingItaly
NCT07881172
Prospective Multicenter Study of the Genomic, Transcriptomic, and Biological Profile of Patients With Neuroblastoma
Istituto Giannina Gaslini
Registry updated 19 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT04755205
A Natural History Study of Children and Adults With Olfactory Neuroblastoma
National Cancer Institute (NCI)
Registry updated 16 Oct 2026
Registry record: ClinicalTrials.govNo phase5 sites
RecruitingUnited States
NCT01109394
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
National Cancer Institute (NCI)
Registry updated 16 Oct 2026
Registry record: ClinicalTrials.govPhase 27 sites
RecruitingUnited States
NCT06057948
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Registry updated 14 Oct 2026
Registry record: ClinicalTrials.govPhase 329 sites
Not yet recruitingGermany
2024-517295-37-00
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR
University Of Cologne
Registry updated 13 Oct 2026
Registry record: EU CTISPhase 11 site
RecruitingUnited States
NCT07087002
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Stanford University
Registry updated 9 Oct 2026
Registry record: ClinicalTrials.govPhase 15 sites
RecruitingUnited States
NCT02013336
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
South Plains Oncology Consortium
Registry updated 8 Oct 2026
Registry record: ClinicalTrials.govPhase 1/224 sites
RecruitingCanada, United States
NCT06541262
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
Registry updated 6 Oct 2026
Registry record: ClinicalTrials.govPhase 1/27 sites
RecruitingUnited States
NCT06721689
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Theodore Laetsch
Registry updated 6 Oct 2026
Registry record: ClinicalTrials.govPhase 12 sites
RecruitingTaiwan
NCT07688252
Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma
Chang Gung Memorial Hospital
Pre-treatment window Registry sentence: “Must have had no prior systemic therapy, or have only completed the first cycle of induction chemotherapy under the TPOG N2020-HR protocol.”
Registry updated 6 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06479811
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “No prior therapy is needed for participants with other histologic subtypes.”
Registry updated 6 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingUnited States
NCT07527169
A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma
M.D. Anderson Cancer Center
Registry updated 5 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT00588068
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
Memorial Sloan Kettering Cancer Center
Registry updated 5 Oct 2026
Registry record: ClinicalTrials.govNo phase2 sites
RecruitingUnited States
NCT06000787
MCT for the Harvard/UCSF ROBIN Center
Brigham and Women's Hospital
Registry updated 1 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingChina
NCT07318831
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
Tianjin Medical University Cancer Institute and Hospital
Registry updated 1 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States59 open trials
- China26 open trials
- Canada13 open trials
- France11 open trials
- Germany10 open trials
- Spain10 open trials
- Netherlands9 open trials
- Italy8 open trials
- Denmark7 open trials
- United Kingdom6 open trials
- Norway5 open trials
- Australia4 open trials
- Belgium4 open trials
- Sweden4 open trials
- Israel3 open trials
- Czechia3 open trials
- Slovakia3 open trials
- Russia3 open trials
- Austria3 open trials
- Poland3 open trials
- Taiwan2 open trials
- Brazil2 open trials
- Greece2 open trials
- Japan2 open trials
- Finland2 open trials
- Switzerland2 open trials
- Colombia1 open trials
- Chile1 open trials
- Hungary1 open trials
- South Korea1 open trials
- Puerto Rico1 open trials
- New Zealand1 open trials
- Hong Kong1 open trials
- Ireland1 open trials
- Iran1 open trials
- Lithuania1 open trials
- Thailand1 open trials
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
Berlin, Germany
0 trials · 26 publications · ROR
Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
0 trials · 26 publications · ROR
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
44 trials · 19 publications · ROR
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Boston, United States
0 trials · 57 publications · ROR
Deutsches Konsortium für Translationale Krebsforschung
Heidelberg, Germany
0 trials · 40 publications · ROR
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
Moscow, Russia
0 trials · 22 publications · ROR
Frederick National Laboratory for Cancer Research
Frederick, United States
0 trials · 31 publications · ROR
Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease
Guangzhou, China
0 trials · 22 publications · ROR
National Center for Advancing Translational Sciences
Rockville, United States
0 trials · 19 publications · ROR
Rutgers, The State University of New Jersey
New Brunswick, United States
0 trials · 17 publications · ROR
Second Affiliated Hospital of Nanjing Medical University
Nanjing, China
0 trials · 30 publications · ROR
The University of Texas MD Anderson Cancer Center
Houston, United States
2 trials · 27 publications · ROR
The University of Texas Southwestern Medical Center
Dallas, United States
2 trials · 16 publications · ROR
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
1 trials · 32 publications · ROR
University Medical Center of the Johannes Gutenberg University Mainz
Mainz, Germany
2 trials · 16 publications · ROR
University of North Carolina at Chapel Hill
Chapel Hill, United States
0 trials · 36 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Phase changed: Phase 1/2 → Phase 1
Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma
NCT06485947 · Phase 1 · Austria, Germany, Spain, France, Italy, Netherlands
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 2
NCT03709680 · Phase 2 · Brazil, Canada, Czechia, Germany, Spain, France
Source: ClinicalTrials.govClosed for recruitment
NCT03363373 · Phase 2 · Canada, Germany, Denmark, Spain, France, United Kingdom
Source: ClinicalTrials.govOpened for recruitment
NCT03363373 · Phase 2 · Canada, Germany, Denmark, Spain, France, United Kingdom
Source: ClinicalTrials.govOpened for recruitment
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
NCT04837547 · Phase 1 · United States
Source: ClinicalTrials.govStatus changed: Running, not recruiting → Completed
A Study of Avutometinib for People With Solid Tumor Cancers
NCT06104488 · Phase 1 · United States
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 1Ended 3 Nov 2026
No phaseEnded 31 Aug 2026
Completed43 participants
NCT07833631
A Prospective Image Reevaluation Study to Assess the Efficacy of 18F-mFBG PET Imaging in Subjects With Neuroblastoma
Phase 3Ended 30 Aug 2026
Phase 1Ended 26 Aug 2026
Phase 1/2Ended 3 Aug 2026
Completed374 participants
NCT00911560
Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma
Phase 3Ended 20 Jul 2026
Phase 2Ended 31 Mar 2026
Completed42 participants
NCT03786783
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
No phaseEnded 31 Mar 2026
Completed10000 participants
NCT00904241
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
- Factors Impacting Overall Survival Post-Relapse in High-Risk Neuroblastoma: Children's Oncology Group Outcomes From 2000 to 2019. · Pediatric blood & cancer, 2026
No phaseEnded 26 Mar 2026
Completed1229 participants
NCT06822842
Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large Models
Phase 2Ended 18 Feb 2026
Completed225 participants
NCT02308527
Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children
Phase 1/2Ended 4 Feb 2026
Phase 2Ended 31 Dec 2025
Phase 3Ended 31 Dec 2025
Completed1449 participants
NCT00026312
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase 1Ended 31 Dec 2025
Phase 1Ended Dec 2025
Completed26 participants
NCT02909777
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
No phaseEnded 20 Oct 2025
Phase 2Ended 29 Sept 2025
Completed59 participants
NCT03033303
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
Phase 1Ended Aug 2025
Completed19 participants
NCT00085930
Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients
Phase 1/2Ended 19 Aug 2025
Phase 2Ended 6 Aug 2025
Completed128 participants
NCT03709680
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Phase 1Ended 28 Jul 2025
Completed85 participants
NCT02650648
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
No phaseEnded 15 Jul 2025
Phase 1/2Ended May 2025
Completed7 participants
NCT00703222
A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells
Early Phase 1Ended 1 May 2025
Completed78 participants
NCT02245997
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma
No phaseEnded 31 Mar 2025
Phase 1/2Ended 13 Feb 2025
Phase 1Ended 31 Jan 2025
Phase 3Ended 17 Jan 2025
Phase 2Ended 31 Dec 2024
Phase 2Ended 31 Dec 2024
Phase 2Ended 31 Dec 2024
Phase 2Ended 31 Dec 2024
Phase 1Ended 10 Dec 2024
Completed25 participants
NCT00638898
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
Phase 2Ended 9 Dec 2024
Phase 1Ended 24 Nov 2024
Completed7 participants
NCT02076906
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors
No phaseEnded 17 Oct 2024
Completed41 participants
NCT00695279
Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
Phase 1Ended 1 Oct 2024
Completed41 participants
NCT03936465
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
Phase 2Ended 30 Sept 2024
Phase 1Ended 24 Sept 2024
Completed25 participants
NCT04853017
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Phase 1Ended 30 Aug 2024
Phase 2Ended 9 Jul 2024
Completed11 participants
NCT05012098
Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).
- Bintrafusp alfa for patients with recurrent or metastatic olfactory neuroblastoma. · Cancer immunology, immunotherapy : CII, 2026
Phase 2Ended 30 Jun 2024
Phase 1Ended 30 Jun 2024
Completed150 participants
NCT01798004
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Phase 1Ended 24 May 2024
Phase 1Ended 13 Mar 2024
Completed62 participants
NCT02085148
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Phase 2Ended 12 Mar 2024
Completed5 participants
NCT05302921
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
No phaseEnded 5 Mar 2024
Completed95 participants
NCT06851221
Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma
Phase 1Ended 23 Feb 2024
Phase 2Ended 20 Feb 2024
Phase 1Ended 2 Feb 2024
Completed24 participants
NCT03507491
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
No phaseEnded 26 Jan 2024
Completed84 participants
NCT03686566
Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics]
Phase 1/2Ended 19 Jan 2024
Completed16 participants
NCT02139397
Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
No phaseEnded 18 Jan 2024
No phaseEnded 17 Jan 2024
Completed52 participants
NCT01802567
Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer
No phaseEnded 31 Dec 2023
Completed240 participants
NCT04474678
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
Phase 1Ended 30 Dec 2023
Completed12 participants
NCT02765243
Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma
Phase 1Ended 30 Dec 2023
Completed30 participants
NCT02030964
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
No phaseEnded 30 Nov 2023
Completed50 participants
NCT06190574
Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid Blastoma
- Characteristics and prognostic value of pre-treatment 18F-FDG PET in neuroblastoma. · European journal of nuclear medicine and molecular imaging, 2026
Not medical advice. fetched 6 Nov 2026